Home / Business and Economy / Mankind Pharma Profit Soars 7.5% in Q3

Mankind Pharma Profit Soars 7.5% in Q3

3 Feb

Summary

Net profit rose 7.5% to ₹408.7 crore in Q3, a strong recovery.
Revenue increased 11.5% to ₹3,567 crore, driven by steady expansion.
Performance shows rebound after Q2 challenges like GST and monsoon.

Mankind Pharma has reported a substantial 7.5% year-on-year rise in net profit for the third quarter, reaching ₹408.7 crore. This financial upswing signifies a strong recovery from earlier setbacks in the fiscal year.

The company's revenue for the quarter experienced an 11.5% increase, totaling ₹3,567 crore. This growth was underpinned by consistent sales expansion and a slight improvement in operating margins, which moved to 25.8%.

This positive outcome contrasts with the second quarter, which saw profitability pressures despite revenue growth. Factors like GST disruptions and monsoon-related issues had impacted sales and consumer healthcare demand.

Mankind Pharma's stock closed on the NSE with a notable gain of 4.78%, indicating investor confidence following the improved quarterly results.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.